SecBot SecBot
DEFA14A ·Filed Jun 4, 2026

SNDX

Syndax Pharmaceuticals Inc
NEUTRAL
Impact 4/10
Horizondays Processed5mo ago SEC0001193125-26-256557
Proxy solicitation materials
Actionable Insight • Neutral

The vote on Proposal No. 4 is the key catalyst, ISS opposition creates uncertainty but the company's corrected dilution figures and below-benchmark burn rate may sway institutional holders. Monitor ISS vote analytics and Glass Lewis support for pass/fail signal ahead of June 10 meeting. If the plan fails, Syndax would lack equity grant capacity for talent retention during commercial buildout.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$18.02
T+0 close · Jun 4, 2026 · via day close
Latest settled
+8.44%
T+60 · $19.54
Vs SPY
+6.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 4 $18.02entry
  2. T+1 · 6mo ago −3.77%α −1.18% · $17.34
  3. T+5 · 5mo ago −0.61%α +1.94% · $17.91
  4. T+20 · 4mo ago +21.09%α +22.46% · $21.82
  5. T+60 · 3mo ago +8.44%α +6.55% · $19.54
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Syndax Pharmaceuticals filed DEFA14A definitive additional proxy materials urging shareholders to vote FOR Proposal No. 4 (2026 Equity Incentive Plan) at the June 10, 2026 annual meeting. The filing rebuts ISS's against recommendation by correcting the share count for the 5,060,185 shares canceled upon the 2015 Plan's expiration, reducing total potential basic dilution from ISS's 35.51% to 27.93%. The plan requests 7.2 million new shares with investor-friendly features (no evergreen, no repricing, clawback policy, 12-year modeled capacity).

Key Financial Metrics

Vote
shareholder proposal
Meeting
2026-06-10

Key Facts

  • Annual meeting scheduled June 10, 2026; board unanimously recommends FOR all proposals, specifically Proposal No. 4 (2026 Equity Incentive Plan)
  • ISS recommended against Proposal No. 4; Glass Lewis recommended FOR
  • 2026 Plan requests 7,200,000 new shares; replaces expired 2015 Plan
  • 5,060,185 shares canceled upon 2015 Plan expiration in March 2026
  • Total potential basic dilution revised to 27.93% (vs ISS's 35.51% using pre-cancellation figures)
  • 3-year value-adjusted burn rate of ~4.44% is below ISS's 6.23% benchmark for Russell 3000/GICS 3520 companies
  • Plan includes no evergreen, no repricing, clawback policy, no single-trigger change-in-control vesting, annual director compensation cap of $1,000,000 ($1,500,000 for first-year/chair)
  • 88,595,948 shares outstanding as of April 21, 2026 record date

Financial Impact

7,200,000 new shares requested, representing 8.13% basic dilution; total potential basic dilution 27.93% including unvested/exercised grants; SVT of new shares valued at $113,472,000

dilutionshare countequity compensation

Risk Factors

  • Plan may fail if ISS-influenced institutional holders vote against, leaving Syndax without equity compensation capacity
  • 27.93% total potential dilution is still elevated and may concern governance-focused investors
  • Commercial-stage execution risk with two recently approved products (Revuforj late 2024, Niktimvo early 2025) requires significant hiring

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-256557
Document: 0001193125-26-256557-index-headers.html0001193125-26-256557
Document: 0001193125-26-256557-index.html0001193125-26-256557
Document: 0001193125-26-256557.txt0001193125-26-256557

US Market Status

Market Closed · Opens in 7h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026